CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: PRMT5 was highly expressed in CD34+ cells from CML patients in a STAT5-dependent manner, and shRNA-mediated silencing of Prmt5 or its inhibition in a murine model of CML significantly prolonged survival and impaired the self-renewal capacity of LSCs45.